MIRAGEN Trademark

Trademark Overview

On Tuesday, July 21, 2009, a trademark application was filed for MIRAGEN with the United States Patent and Trademark Office. The USPTO has given the MIRAGEN trademark a serial number of 77785768. The federal status of this trademark filing is REGISTERED AND RENEWED as of Tuesday, March 31, 2020. This trademark is owned by miRagen Therapeutics, Inc.. The MIRAGEN trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of therapeutic drugs for treatment of cardiovascular and muscle disease
miragen

General Information

Serial Number77785768
Word MarkMIRAGEN
Filing DateTuesday, July 21, 2009
Status800 - REGISTERED AND RENEWED
Status DateTuesday, March 31, 2020
Registration Number3754412
Registration DateTuesday, March 2, 2010
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 15, 2009

Trademark Statements

Goods and ServicesResearch and development of therapeutic drugs for treatment of cardiovascular and muscle disease

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, July 24, 2009
Primary Code042
First Use Anywhere DateSunday, January 1, 2006
First Use In Commerce DateFriday, July 13, 2007

Trademark Owner History

Party NamemiRagen Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressBoulder, CO 80301
Party NamemiRagen Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBoulder, CO 80301
Party NamemiRagen Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoulder, CO 80301

Trademark Events

Event DateEvent Description
Friday, June 11, 2021WITHDRAWAL OF ATTORNEY GRANTED
Friday, June 11, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Tuesday, March 31, 2020NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Tuesday, March 31, 2020REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Tuesday, March 31, 2020REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Tuesday, March 31, 2020CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, February 4, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, February 4, 2020TEAS SECTION 8 & 9 RECEIVED
Wednesday, December 4, 2019REVIEW OF CORRESPONDENCE COMPLETE - POWER OF ATTORNEY ENTERED
Tuesday, December 3, 2019TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Saturday, March 2, 2019COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Wednesday, February 3, 2016NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Wednesday, February 3, 2016REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Wednesday, February 3, 2016CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, November 24, 2015TEAS SECTION 8 & 15 RECEIVED
Tuesday, November 24, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, March 2, 2015COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Monday, September 16, 2013TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, March 2, 2010REGISTERED-PRINCIPAL REGISTER
Tuesday, December 15, 2009OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 15, 2009PUBLISHED FOR OPPOSITION
Monday, November 9, 2009LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, November 9, 2009ASSIGNED TO LIE
Monday, October 26, 2009APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, October 23, 2009EXAMINER'S AMENDMENT ENTERED
Friday, October 23, 2009NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, October 23, 2009EXAMINERS AMENDMENT E-MAILED
Friday, October 23, 2009EXAMINERS AMENDMENT -WRITTEN
Thursday, October 22, 2009ASSIGNED TO EXAMINER
Friday, July 24, 2009NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, July 24, 2009NEW APPLICATION ENTERED IN TRAM

Related Keywords

miragen cardiovascular muscle disease treatment drugs development therapeutic research